Quarter
Charts

IRADIMED CORPORATION

IRMD

CIK 0001325618 · Quarterly mode · latest period FY2026 (Q1) (ending 2026-03-31) · sourced from SEC EDGAR

At a glance · FY2026 (Q1)

Revenue
$22M
↑+12.6% +$2Mvs FY2025 (Q1)
Operating Income
$7M
↑+33.2% +$2Mvs FY2025 (Q1)
Net Income
$6M
↑+24.1% +$1Mvs FY2025 (Q1)
Gross Profit
$17M
↑+13.3% +$2Mvs FY2025 (Q1)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
64/100
  • Profitability
    89ROIC 22.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 7.98 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    47Asset Turnover 0.81x (1.0+ = capital-efficient)
  • Growth
    59Revenue YoY +12.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    87Op Margin 32.9% · trend +2.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project IRMD's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

23%

Trailing 3-yr CAGR was 23.1%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$41.40
Total enterprise IV
$532M
Diluted shares
0.01B
Terminal PV
$410M (77% of total)
Year-5 FCF
$48M
YearProjected FCFDiscounted PV
+1$21M$19M
+2$26M$21M
+3$32M$24M
+4$39M$27M
+5$48M$30M
Terminal$661M$410M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$4M
investment in PP&E
Dividends paid (TTM)
$15M
cash returned to holders
Stock buybacks (TTM)
—
share count reduction
Stock-based comp (TTM)
$3M
non-cash dilution

Balance sheet · 2026-03-31

latest filed snapshot
Total assets
$114M
everything owned
Total liabilities
$16M
everything owed
Stockholders' equity
$99M
shareholder claim

Recent performance · 52 quarters

Revenue↑+12.6% +$2M
$22M
Net Income↑+24.1% +$1M
$6M
Free Cash Flow↑+1225.5% +$7M
$8M
Operating Margin↑+5.1pts
32.9%

Drill down

IRMD Sankey

See IRADIMED CORPORATION's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

IRMD Charts

52 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

IRMD Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics